[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489449":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":62,"centralContacts":66,"locations":75,"responsibleParty":98,"collaborators":100,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":48,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":112,"minAge":113,"maxAge":48,"enrollmentInfo":114,"targetDuration":48,"studyType":117,"phases":118,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":78,"whyStopped":48,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8,13,17,26],{"label":9,"type":6,"description":10,"interventionNames":11},"Younger Lean Group","Participants will be aged 18-30 years and have a BMI of 18.5 - 24.9 kg\u002Fm2",[12],"Procedure: Abdominal adipose tissue biopsy",{"label":14,"type":6,"description":15,"interventionNames":16},"Older Lean Group","Participants will be over 65 years of age with a BMI of 18.5 to 24.9 kg\u002Fm2",[12],{"label":18,"type":19,"description":20,"interventionNames":21},"Older Obese Group","EXPERIMENTAL","Participants will be over 65 years of age with a BMI of 30-39.9 kg\u002Fm2.",[22,23,24,25,12],"Other: Lifestyle Intervention","Drug: Dasatinib 100 MG","Drug: Quercetin 1000mg","Drug: Placebo",{"label":27,"type":19,"description":28,"interventionNames":29},"Younger Obese Group","Participants will be ages 18-30 years and have a BMI OF 30.0-39.9 kg\u002Fm2",[12],[31,37,44,49,55],{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Lifestyle Intervention","1. Exercise: Subjects will undergo a combined aerobic and resistance exercise intervention. The investigators propose a multi-modal training program because they improve metabolic outcomes and adding resistance training reduces the risk of muscle loss during weight loss. Subjects will exercise in the gym for three sessions per week for 10 weeks under supervision of an exercise physiologist. On each session, aerobic exercise will be followed by resistance exercise.\n2. Diet: The aim of the dietary intervention is to reduce caloric intake sufficient to result in 8-10% weight loss, while incorporating behavioral and dietary strategies to maximize adherence and to minimize risk of muscle and bone loss. Subjects will attend small-group sessions led by a dietitian for changing their dietary composition to follow American Heart Association (AHA)\u002FAmerican College of Cardiology (ACC) guidelines.",[18],[36],"Exercise and Diet",{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Dasatinib 100 MG","100 mg of dasatinib (D) daily for 3 consecutive days plus quercetin (Q) for the same 3 consecutive days, followed by a 25-day (+\u002F- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.",[18],[43],"Sprycell",{"type":38,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Quercetin 1000mg","Quercetin (Q) (4) 250 mg capsules daily (total 1000 mg daily) plus dasatinib (D) same 3 consecutive days, followed by a 25-day (+\u002F- 2 day) no-drug period to complete a single round. This will be repeated twice more until completing 3 rounds total in approximately 10 consecutive weeks.",[18],null,{"type":38,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"Placebo","Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets\u002F capsules, and frequency as the senolytic arm.",[18],[54],"Placebo capsule",{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"PROCEDURE","Abdominal adipose tissue biopsy","All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular\u002Fmolecular profiling via snRNA-seq",[14,18,9,27],[61],"Subcutaneous abdominal adipose tissue biopsy",[63],{"name":64,"affiliation":5,"role":65},"Nicolas Musi, MD","PRINCIPAL_INVESTIGATOR",[67,71],{"name":64,"role":68,"phone":69,"phoneExt":48,"email":70},"CONTACT","210-562-6140","nicolas.musi@cshs.org",{"name":72,"role":68,"phone":73,"phoneExt":48,"email":74},"Arianne Aslamy, MD","424-315-0685","Arianne.Aslamy@cshs.org",[76],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Cedars Sinai Medical Center","RECRUITING","Los Angeles","California","90048","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-118.24368,34.05223,{"lat":88,"lon":87},[91,94],{"name":92,"role":68,"phone":93,"phoneExt":48,"email":70},"Nicolas Musi","12106305001",{"name":95,"role":68,"phone":96,"phoneExt":48,"email":97},"Sandra Gomez","210-777-0629","Sandra.Gomez3@cshs.org",{"type":65,"investigatorFullName":64,"investigatorTitle":99,"investigatorAffiliation":5,"oldNameTitle":48,"oldOrganization":48},"Staff Physician IV",[101],{"name":102,"class":103},"National Institute on Aging (NIA)","NIH","100489449","phase-2-single-nuclei-rna-seq-to-map-adipose-cellular-populations-and-senescent-cells-in-older-subjects-100489449",false,"NCT05653258","Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older Subjects","Inclusion Criteria:\n\n1. Both Sexes\n2. Age: younger lean group 18-30 years with BMI 18.5-24.9 kg\u002Fm2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9\n3. All races and ethnic groups\n4. Community dwelling\n5. Sedentary (≤1.5 h of exercise per week)\n6. Nondiabetic (fasting plasma glucose \\\u003C 126 mg\u002Fdl, 2-h glucose during oral glucose tolerance test (OGTT) \\\u003C 140mg\u002Fdl, and A1c \\\u003C 6.5%\n7. For all female participants who are women of childbearing potential (WOCBP), who are not pregnant or breast feeding, at least one of the following conditions must apply:\n\n   A documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy Use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency (implantable progesterone-only hormone contraception, intrauterine hormone releasing system, bilateral tubal occlusion, vasectomized partner) during the intervention period of the study and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug.\n\n   Use of a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), with high user dependency, (oral\u002Fintravaginal\u002Finjectable combined estrogen and progesterone contraception, oral\u002Finjectable progesterone only hormone contraception, sexual abstinence) during the intervention period and for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug. In addition to the highly effective methods: male or female condom with or without spermicide; cervical cap, diaphragm, or sponge with spermicide; a combination of male condom with either cervical cap, diaphragm, or sponge with spermicide.\n8. ECG value after 10 minutes of resting in the supine position in the following ranges:\n\n120ms\\\u003CPR\\\u003C220ms: QRS\\\u003C120ms; QTc\\\u003C430ms for males and QTc\\\u003C450ms for females and normal ECG tracing, unless the investigator considers the ECG abnormality to be not clinically relevant.\n\nExclusion Criteria:\n\n1. Diabetes, clinically diagnosed or HbA1c \\> 6.5% and\u002For fasting plasma glucose \\> 126 mg\u002Fdl and\u002For use of anti-diabetic medications.\n2. Participating in \\> 1.5 h of structured exercise\u002Fweek\n3. Unstable weight (\\>3% change in last 3 months)\n4. Neurological, musculoskeletal, or other conditions that may limit subject's ability to complete study physical assessment and training\n5. Active autoimmune\u002Finflammatory disease including: rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, inflammatory bowel disease\n6. Laboratory parameters outside the normal range:\n\n   * impaired kidney function (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m² as calculated by the CKD-EPI equation);\n   * impaired liver function (AST or ALT level \\> 2 times upper limit of normal (ULN);\n   * total Bilirubin level \\> 1.5 times ULN;\n   * TSH \\> 1.5 times ULN or \\\u003C lower limit of normal (LLN);\n   * Hemoglobin \\\u003C10.0 g\u002Fdl; Platelets \\\u003C125,000 cell\u002Fmm³;\n   * Platelets \\\u003C 125,000 cell\u002Fmm³\n   * Prothrombin time (PT) \\> 1.0 times ULN\n   * Partial prothrombin time (PTT) \\> 1.0 times ULN.\n7. Active gastrointestinal disease; coagulopathy; GI bleed within 6 months\n8. Clinically significant heart disease (e.g. NYH Classification \\>II; ischemia)\n9. Peripheral vascular disease (claudication)\n10. QTc prolongation \\>45 msec\n11. Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication (see section 5.3)\n12. Use of quinolone antibiotics or any other drugs that may prolong the QTc interval (see section 5.3)\n13. Pulmonary disease (COPD), severe asthma or exercise-induced asthma\n14. Recent systemic or pulmonary embolus\n15. Uncontrolled blood pressure (systolic BP\\>170, diastolic BP\\>95 mmHg)\n16. Smoking, alcohol use (history of regular alcohol consumption exceeding 7 drinks\u002Fweek for female participants or 14 drinks\u002Fweek for male participants. 1 drink = 5 ounces \\[150ml\\] of wine or 12 ounces \\[360ml\\] of beer or 1.5 ounces \\[45ml\\] of hard liquor) or recreational drug use (other than marijuana)\n17. Pregnant or breastfeeding\n18. Postmenopausal women new (within 6 months) to systemic hormone replacement therapy\n19. Previous bariatric surgery\n20. History of stroke with motor disability\n21. Recent (3 years) treated cancer other than basal cell carcinoma\n22. Acute or chronic infection\n23. Medication that might interfere with metabolic studies (weight loss medication, systemic steroids, immunosuppressants) within 6 months (see section 5.3)\n24. Potentially senolytic agents within the last 6 months: fisetin, quercetin, luteolin, dasatinib, piperlongumine, or navitoclax (see section 5.3)\n25. History of allergy to dasatinib, quercetin and\u002For lidocaine.\n26. Concurrent enrollment in another interventional trial.",true,"ALL","18 Years",{"count":115,"type":116},160,"ESTIMATED","INTERVENTIONAL",[119,120],"PHASE2","PHASE3","All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular\u002Fmolecular profiling via snRNA-seq and metabolic\u002Fphysiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).",[123,124],"Obesity","Healthy Lifestyle",[126,127,128],"Lifestyle intervention","Single RNA sequencing","Cell Senescence","2026-03-16",{"date":131,"type":132},"2026-03-18","ACTUAL",{"date":134,"type":132},"2023-10-17",{"date":136,"type":116},"2028-02-01",{"name":5,"class":6},1]